Transaction DateRecipientSharesTypePriceValue
24th November 2020James J Marino38,774Open or private purchase$0.26$10,003.69
11th June 2020Diane C. Young2,115Open or private purchase$4.73$10,003.95
10th June 2020Sarah Cavanaugh1,050Open or private purchase$4.83$5,071.50
9th June 2020Tibor Keler5,000Open or private purchase$2.99$14,954.00
9th June 2020Margo Heath Chiozzi1,000Open or private purchase$3.01$3,005.00
9th June 2020Samuel Bates Martin9,750Open or private purchase$3.05$29,737.50
9th June 2020James J Marino8,305Open or private purchase$3.00$24,915.00
9th June 2020Anthony S Marucci15,000Open or private purchase$3.06$45,900.00
25th November 2019James J Marino150,000Open or private purchase$0.20$30,000.00
25th September 2019James J Marino7,260Open or private purchase$1.60$11,616.00
Celldex Therapeutics
Celldex Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Ticker: CLDX
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 744218
Employees: 130
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags